RESUMEN
We have biologically and biochemically evaluated a structurally diverse group of HIV-1-specific reverse transcriptase (RT) inhibitors and determined that the members of this class share many common properties. These include reproducible and selective antiviral activity against a panel of biologically distinct laboratory and clinical strains of HIV-1, activity against HIV-1 in a wide variety of cultured and fresh human cells, and potent inhibition of HIV-1 RT when evaluated using a heteropolymeric ribosomal RNA template assay. Each of the HIV-1-specific compounds was capable of inhibiting HIV replication when challenged at high m.o.i., further distinguishing them from the nucleoside analogs 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine (ddC). When tested in combination with AZT, each of the HIV-1-specific compounds synergistically inhibited the replication of HIV-1. HIV-1 isolates resistant to different HIV-1-specific inhibitors exhibited heterogeneous patterns of cross-resistance to other members of this pharmacologic class. Four distinct phenotypic classes have been defined through the use of drug-resistant virus isolates which derive from distinct mutations in the RT. These results indicate that the various subgroups of HIV-1-specific inhibitors interact differently with HIV-1 RT, suggesting important potential implications for drug combination therapeutic strategies.
Asunto(s)
Antivirales/farmacología , VIH-1/efectos de los fármacos , Inhibidores de la Transcriptasa Inversa , Línea Celular , Evaluación de Medicamentos , Interacciones Farmacológicas , Farmacorresistencia Microbiana , Transcriptasa Inversa del VIH , Humanos , Fenotipo , Reproducibilidad de los Resultados , Zidovudina/farmacologíaRESUMEN
A series of benzothiadiazine derivatives were screened against the human immunodeficiency virus (HIV) and certain structure-activity relationships were defined for anti-HIV activity in this chemical class. The selected representative NSC 287474 was a highly potent inhibitor of HIV-induced cell killing and HIV replication in a variety of human cell lines, as well as in fresh human peripheral blood lymphocytes and macrophages. The compound was active against a panel of biologically diverse laboratory and clinical strains of HIV-1, including the AZT-resistant strain G910-6. However, the agent was inactive against HIV-2, and also against both nevirapine- and pyridinone-resistant strains (N119 and A17) of HIV-1, which are cross-resistant to several structurally diverse nonnucleoside reverse transcriptase inhibitors. The compound selectively inhibited HIV-1 reverse transcriptase, but not HIV-2 reverse transcriptase. Combination of NSC 287474 with AZT synergistically inhibited HIV-1-induced cell killing in vitro. The compound did not inhibit the replication of the Rauscher murine leukemia retrovirus or the simian immunodeficiency virus. The benzothiadiazine class of compounds represents a new active anti-HIV-1 chemotype within the diverse group of nonnucleoside reverse transcriptase inhibitors.
Asunto(s)
Antivirales/farmacología , Benzotiadiazinas/farmacología , VIH-1/efectos de los fármacos , VIH-2/efectos de los fármacos , Inhibidores de la Transcriptasa Inversa , Secuencia de Bases , Línea Celular , Células Cultivadas , Evaluación Preclínica de Medicamentos , Farmacorresistencia Microbiana , Sinergismo Farmacológico , Transcriptasa Inversa del VIH , VIH-1/fisiología , VIH-2/fisiología , Humanos , Datos de Secuencia Molecular , Relación Estructura-Actividad , Replicación Viral/efectos de los fármacos , Zidovudina/farmacologíaRESUMEN
Thiazolobenzimidazole (NSC 625487) was a highly potent inhibitor of human immunodeficiency virus-induced cell killing and viral replication in a variety of human cell lines, as well as fresh human peripheral blood lymphocytes and macrophages. The compound was active against a panel of biologically diverse laboratory and clinical strains of HIV-1, including the AZT-resistant strain G910-6. However, the agent was inactive against HIV-2 and a pyridinone-resistant strain (A17) of HIV-1, a strain which is cross-resistant to several structurally diverse members of a common pharmacologic class of nonnucleoside reverse transcriptase inhibitors. The compound selectively inhibited HIV-1 reverse transcriptase but not HIV-2 reverse transcriptase. Combinations of thiazolobenzimidazole with either AZT or ddI synergistically inhibited HIV-1 induced cell killing in vitro. Thiazolobenzimidazole also inhibited the replication of the Rauscher murine leukemia retrovirus. Thus, thiazolobenzimidazole is a new active anti-HIV-1 chemotype and may represent a subclass of nonnucleoside reverse transcriptase inhibitors with an enhanced range of anti-retroviral activity.
Asunto(s)
Antivirales/farmacología , Bencimidazoles/farmacología , VIH-1/efectos de los fármacos , Inhibidores de la Transcriptasa Inversa , Tiazoles/farmacología , Secuencia de Bases , Línea Celular , ADN de Cadena Simple , Didanosina/farmacología , Sinergismo Farmacológico , Transcriptasa Inversa del VIH , VIH-1/enzimología , Humanos , Virus de la Leucemia Murina/efectos de los fármacos , Datos de Secuencia Molecular , Estructura Molecular , Zidovudina/farmacologíaRESUMEN
A series of variously substituted diarylsulfones and related derivatives were found to prevent human immunodeficiency virus type 1 (HIV-1) replication and HIV-1-induced cell killing in vitro. One of the more potent derivatives, 2-nitrophenyl phenyl sulfone (NPPS), completely protected human CEM-SS lymphoblastoid cells from the cytopathic effects of HIV-1 in cell culture at 1 to 5 microM concentrations. HIV-1 replication, as assessed by the production of infectious virions, viral p24 antigen, and virion reverse transcriptase (RT), was inhibited by NPPS at similar concentrations. There was no evidence of direct cytotoxicity of the drug at concentrations below 100 microM. A variety of other CD4+ T-cell lines as well as cultures of peripheral blood leukocytes and monocytes were protected from HIV-1-induced cytopathicity and/or viral replication. NPPS also inhibited several distinctly different strains of HIV-1 but was ineffective against three strains of HIV-2. Biochemical studies revealed that NPPS inhibited HIV-1 RT but not HIV-2 RT. NPPS had no direct effect on HIV-1 virions, nor did it block the initial binding of HIV-1 to target cells. Time-limited treatments of cells with NPPS found that NPPS had to be present continuously in culture to provide maximum antiviral protection. In addition, HIV-1 replication in cells in which infection was already fully established or in chronically infected cells was also unaffected by NPPS. We conclude that NPPS acts in a reversible manner as a nonnucleoside HIV-1-specific RT inhibitor. Although markedly different in structure from a larger, structurally diverse group of known HIV-1-specific nonnucleoside RT inhibitors, NPPS shares several of the biological properties that characterize this emerging new pharmacologic class.
Asunto(s)
Antivirales/farmacología , VIH-1/enzimología , Inhibidores de la Transcriptasa Inversa , Sulfonas/farmacología , Linfocitos T CD4-Positivos/efectos de los fármacos , Línea Celular , Supervivencia Celular/efectos de los fármacos , Efecto Citopatogénico Viral/efectos de los fármacos , Transcriptasa Inversa del VIH , VIH-1/efectos de los fármacos , VIH-1/fisiología , Humanos , Indicadores y Reactivos , Relación Estructura-Actividad , Replicación Viral/efectos de los fármacosRESUMEN
Sixty-eight adults and nine children infected with human immunodeficiency virus type 1 (HIV-1) were evaluated consecutively for the presence and amount of cell-free infectious virus in their plasma. Viremia was detected in 18 of 68 adults and in five of nine children; titers ranged from 10 to 100,000,000 TCID/ml plasma. Among the adults, none of 19 asymptomatic patients, 4 of 34 AIDS-related complex patients, and 14 of 15 AIDS patients had cell-free infectious virus in their plasma. None of 35 adult subjects with CD4+ lymphocyte counts greater than 400/mm3 were viremic, whereas 3 of 17 with 200-400 CD4+ lymphocytes/mm3 and 15 of 16 individuals with less than 200 CD4+ lymphocytes/mm3 were plasma viremic. In contrast to adults, each of five children infected with HIV-1 in utero or during the perinatal period were plasma viremic regardless of their CD4+ lymphocytes counts (range, 42-2227/mm3), duration of infection, or clinical stage; however, children infected by HIV-1 at older ages were less frequently plasma viremic. Therapy with zidovudine led to a 10- to 10(6)-fold decline in plasma HIV-1 TCID in all eight subjects studied before and after treatment.
Asunto(s)
Linfocitos T CD4-Positivos , Infecciones por VIH/microbiología , VIH-1/crecimiento & desarrollo , Viremia/microbiología , Adulto , Niño , Productos del Gen gag/sangre , Anticuerpos Anti-VIH/sangre , Antígenos VIH/sangre , Proteína p24 del Núcleo del VIH , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/inmunología , VIH-1/aislamiento & purificación , Humanos , Recuento de Leucocitos , Reproducibilidad de los Resultados , Proteínas del Núcleo Viral/sangre , Viremia/tratamiento farmacológico , Viremia/inmunología , Zidovudina/uso terapéuticoRESUMEN
BACKGROUND: Primary infection with the human immunodeficiency virus (HIV-1) frequently causes an acute, self-limited viral syndrome. To examine the relations among viral replication, the immune response of the host, and clinical illness during this initial phase of infection, we undertook a quantitative, molecular, and biologic analysis of infectious HIV-1 in the blood and plasma of three patients with symptomatic primary infection and of a sexual partner of one of them. METHODS: During an eight-week period of primary infection, HIV-1 was cultured frequently in dilutions of plasma and peripheral-blood mononuclear cells (PBMC), and levels of HIV-1 antigen and antibody were determined sequentially by enzyme-linked immunosorbent assay and immunoblotting. Replication-competent HIV-1 proviruses were cloned and characterized biologically. RESULTS: Six to 15 days after the onset of symptoms, high titers of infectious HIV-1 (from 10 to 10(3) tissue-culture-infective doses per milliliter of plasma) and viral p24 antigen were detected in the plasma of all three patients. These titers fell precipitously by day 27, and the decline coincided with an increase in the levels of antiviral antibodies and the resolution of symptoms. Sequential isolates of virus from plasma and PBMC obtained throughout the period of primary infection, as well as virus derived from two molecular proviral clones, were highly cytopathic for normal-donor PBMC and immortalized T cells, despite the marked reduction in the titers of virus in plasma. CONCLUSIONS: Primary, symptomatic HIV-1 infection is associated with high titers of cytopathic, replication-competent viral strains, and during such infection potential infectivity is enhanced. Effective control of HIV-1 replication during primary infection implies the activation of clinically important mechanisms of immune defense that merit further examination in relation to the development of antiviral therapy and vaccines.
Asunto(s)
Síndrome de Inmunodeficiencia Adquirida/microbiología , VIH-1/aislamiento & purificación , Síndrome de Inmunodeficiencia Adquirida/inmunología , Síndrome de Inmunodeficiencia Adquirida/fisiopatología , Adulto , Sangre/microbiología , Ensayo de Inmunoadsorción Enzimática , Productos del Gen gag/inmunología , Anticuerpos Anti-VIH/análisis , Antígenos VIH/análisis , Proteína p24 del Núcleo del VIH , Seropositividad para VIH/inmunología , Seropositividad para VIH/microbiología , Humanos , Leucocitos Mononucleares/microbiología , Masculino , Factores de Tiempo , Proteínas del Núcleo Viral/inmunología , Viremia/inmunología , Viremia/microbiologíaRESUMEN
The reliability of steady-state visual evoked responses (VER's) was determined for nine normal subjects using Fourier analyses with 1.0 and 0.25 Hz bin resolutions. No correlations were found between VER amplitudes and subjects' reports of attention, accommodation, fixation, or perceived organization of the stimulus. Across subjects, there was also no sustained amplitude modulation of the VER by any frequency (including alpha), and frequency drift of the VER did not contribute significantly to its amplitude variability. Modeling, using mixed sine waves to simulate different signal/noise (S/N) ratios, established that a significant portion of VER amplitude variability can be accounted for by noise which occurs at the same frequency as the VER and which is not removed by ensemble averaging.